H. S. Rugo

2.5k total citations
107 papers, 1.3k citations indexed

About

H. S. Rugo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, H. S. Rugo has authored 107 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 30 papers in Cancer Research. Recurrent topics in H. S. Rugo's work include Cancer Treatment and Pharmacology (51 papers), Advanced Breast Cancer Therapies (49 papers) and HER2/EGFR in Cancer Research (24 papers). H. S. Rugo is often cited by papers focused on Cancer Treatment and Pharmacology (51 papers), Advanced Breast Cancer Therapies (49 papers) and HER2/EGFR in Cancer Research (24 papers). H. S. Rugo collaborates with scholars based in United States, United Kingdom and France. H. S. Rugo's co-authors include Lee S. Schwartzberg, Eric P. Winer, Denise A. Yardley, RS Finn, Supriya Gupta, Éric Charpentier, Michael Danso, Anne Blackwood‐Chirchir, J. O’Shaughnessy and Matti Aapro and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

H. S. Rugo

104 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. S. Rugo United States	19	925	370	318	274	201	107	1.3k
Florian Clatot France	24	692 0.7×	401 1.1×	461 1.4×	321 1.2×	115 0.6×	99	1.6k
Antonio Febbraro Italy	18	649 0.7×	314 0.8×	241 0.8×	249 0.9×	253 1.3×	56	1.2k
Tamer M. Fouad United States	19	683 0.7×	291 0.8×	425 1.3×	211 0.8×	158 0.8×	41	1.1k
Albiruni Ryan Abdul Razak Canada	18	661 0.7×	375 1.0×	185 0.6×	410 1.5×	257 1.3×	100	1.3k
Giovanni Fucà Italy	23	1.2k 1.2×	549 1.5×	204 0.6×	382 1.4×	169 0.8×	87	1.8k
Pasquale Rescigno Italy	22	317 0.3×	773 2.1×	397 1.2×	381 1.4×	230 1.1×	82	1.3k
Jay P. Reddy United States	18	356 0.4×	322 0.9×	239 0.8×	215 0.8×	253 1.3×	94	1.1k
Stella D’Oronzo Italy	21	594 0.6×	209 0.6×	171 0.5×	421 1.5×	176 0.9×	46	1.1k
Shinkyo Yoon South Korea	18	565 0.6×	521 1.4×	151 0.5×	239 0.9×	173 0.9×	84	1.1k
Guillermo Villacampa Spain	14	587 0.6×	327 0.9×	264 0.8×	226 0.8×	66 0.3×	90	1.1k

Countries citing papers authored by H. S. Rugo

Since Specialization

Citations

This map shows the geographic impact of H. S. Rugo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. S. Rugo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. S. Rugo more than expected).

Fields of papers citing papers by H. S. Rugo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. S. Rugo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. S. Rugo. The network helps show where H. S. Rugo may publish in the future.

Co-authorship network of co-authors of H. S. Rugo

This figure shows the co-authorship network connecting the top 25 collaborators of H. S. Rugo. A scholar is included among the top collaborators of H. S. Rugo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. S. Rugo. H. S. Rugo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Trivedi, Meghna S., Rebecca Shatsky, Rita Nanda, et al.. (2024). LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial. Annals of Oncology. 35. S1208–S1209. 1 indexed citations

Modi, Shanu, William Jacot, Hiroji Iwata, et al.. (2023). 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. Annals of Oncology. 34. S334–S335. 28 indexed citations

Oliveira, Mafalda, H. S. Rugo, Sacha J. Howell, et al.. (2023). 187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial. ESMO Open. 8(1). 101376–101376. 5 indexed citations

Goetz, Matthew P., Daniel G. Stover, Nusayba A. Bagegni, et al.. (2022). LBA20 Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors. Annals of Oncology. 33. S1387–S1388. 11 indexed citations

Marmé, F., H. S. Rugo, Sara M. Tolaney, et al.. (2022). 214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study. Annals of Oncology. 33. S635–S636. 19 indexed citations

André, Fabrice, H. S. Rugo, Dejan Juric, et al.. (2021). 309P Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1. Annals of Oncology. 32. S498–S499. 1 indexed citations

Emens, Leisha A., Sylvia Adams, Carlos H. Barrios, et al.. (2020). LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Annals of Oncology. 31. S1148–S1148. 44 indexed citations

Iwata, Hitoshi, Leisha A. Emens, Sylvia Adams, et al.. (2020). 49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Annals of Oncology. 31. S1261–S1262. 8 indexed citations

Rugo, H. S., Santosh K. Nanda, & Andrew Koustenis. (2017). Abstract P6-11-12: Subgroup Analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2 metastatic breast cancer (MBC) following chemotherapy. Cancer Research. 77(4_Supplement). P6–11. 3 indexed citations

10.

Rugo, H. S., SM Tolaney, Maura N. Dickler, et al.. (2017). Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC). Cancer Research. 77(4_Supplement). OT2–1. 3 indexed citations

11.

Rugo, H. S., Abhijit Barve, Cornelius F. Waller, et al.. (2017). HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin. European Journal of Cancer. 72. S41–S41. 3 indexed citations

12.

Rugo, H. S., et al.. (2016). A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases. Annals of Oncology. 27. vi97–vi97. 1 indexed citations

13.

Aapro, Matti, Richard J. Gralla, Lee S. Schwartzberg, et al.. (2014). Multicycle Efficacy and Safety of Nepa, a Fixed-Dose Antiemetic Combination of Netupitant and Palonosetron, in Patients Receiving Chemotherapy of Varying Emetogenicity. Annals of Oncology. 25. iv518–iv518. 2 indexed citations

14.

Chien, A. Jo, K. M. Koch, Glenna Auerback, et al.. (2011). A phase I dose and exposure escalation study of 5-day intermittent oral lapatinib (Lp) therapy in patients with HER2-overexpressing breast cancer (BC).. Journal of Clinical Oncology. 29(15_suppl). e11077–e11077. 2 indexed citations

15.

André, Fabrice, Thomas Bachelot, Mario Campone, et al.. (2011). A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC).. Journal of Clinical Oncology. 29(27_suppl). 289–289. 13 indexed citations

16.

Rugo, H. S., et al.. (2011). P1-08-07: Survival in US Women Following an Indication of Metastatic Breast Cancer Diagnosis and Chemotherapy Initiation: A SEER-Medicare Analysis.. Cancer Research. 71(24_Supplement). P1–8. 3 indexed citations

17.

Scott, Janet H., et al.. (2008). Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. Journal of Clinical Oncology. 26(15_suppl). 559–559. 47 indexed citations

18.

Seiter, Karen, Lloyd E. Damon, Claudia Linker, et al.. (1997). A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 11(4). 485–489. 40 indexed citations

19.

Damon, Lauren E., H. S. Rugo, Curt A. Ries, & CA Linker. (1994). Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.. PubMed. 8(4). 535–41. 15 indexed citations

20.

Linker, Claudia, et al.. (1993). Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.. PubMed. 20(4 Suppl 4). 40–8; quiz 49. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact